Clinical Trial Update: Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the pharmacokinetics and postprandial glycemic responses of insulin lispro with or without recombinant human hyaluronid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Humalog (insulin lispro) (insulin lispro)
• Hylenex recombinant human hyaluronidase PH20 (recombinant human hyaluronidase PH20)
• Regular human insulin (human insulin (regular))

Snippet

Sponsor: Halozyme Therapeutics | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2014-08-18